[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qifu Li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":217},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,67,91,120,144,167,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100589505","study-on-the-incidence-of-adrenal-insufficiency-after-surgery-in-primary-aldosteronism-patients-concurrent-with-or-without-autonomous-cortisol-secretion-100589505",false,"NCT06955286","Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion","* A confirmed diagnosis of primary aldosteronism or autonomous cortisol secretion;\n\n  ② Completion of unilateral adrenal surgery;\n\n  ③ Voluntary participation and obtaining informed consent. (2) Exclusion criteria\n* Patients with typical clinical manifestations of Cushing's syndrome;\n\n  * Patients suspected of having bilateral cortisol over-secretion, such as PBMAH or PPNAD; ③ Patients with severe surgical complications, unstable postoperative condition (not due to cortical insufficiency), and difficulty completing the ACTH stimulation test;\n\n    * History of ACTH allergy;\n\n      * Patients requiring long-term hormone therapy for other diseases (such as autoimmune diseases);\n\n        * Severe liver and kidney dysfunction (ALT ≥ 3 times the upper limit of normal; patients undergoing dialysis or with an estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002Fm2); ⑦ History of contralateral adrenal surgery; ⑧ Patients with poor compliance who are unable to complete the study.","ALL","18 Years","70 Years",{"count":19,"type":20},521,"ESTIMATED","OBSERVATIONAL","To evaluate the incidence of adrenal insufficiency after surgery in Primary aldosteronism (PA) patients concurrent with or without autonomous cortisol secretion (ACS). To assess the recovery time of postoperative adrenal insufficiency in patients. And to explore the clinical characteristics and predictive indicators of patients requiring postoperative hormone replacement therapy.",[24,25,26],"Primary Aldosteronism","Autonomous Cortisol Secretion","Adrenal Insufficiency",[24,25,26,28],"ACTH stimulation test","RECRUITING","2026-04-29",{"date":32,"type":33},"2026-05-01","ACTUAL",{"date":35,"type":33},"2025-01-02",{"date":37,"type":20},"2028-12-31",{"name":39,"class":40},"Qifu Li","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100588416","steroids-based-screening-for-primary-aldosteronism-100588416","NCT06941116","Steroids-Based Screening for Primary Aldosteronism","SAFE","Inclusion Criteria:\n\n1. Aged 18-75 years, with no sex restriction.\n2. Diagnosed with hypertension, defined as a systolic blood pressure ≥140 mmHg and\u002For a diastolic blood pressure ≥90 mmHg measured on at least two different days.\n3. Currently receiving at least one antihypertensive medication that interferes with aldosterone or renin (ACEI\u002FARB, β-blockers, dihydropyridine CCBs, or diuretics including MRA) for ≥4 consecutive weeks.\n4. Fully informed about the study procedures and risks, and willing to participate by signing a written informed consent form.\n\nExclusion Criteria:\n\n1. Confirmed secondary hypertension of other etiologies (e.g., renovascular hypertension, renal artery stenosis, reninoma, pheochromocytoma, Cushing's syndrome, Liddle syndrome), excluding obstructive sleep apnea.\n2. Severe cardiac, hepatic, or renal impairment or serious infections, including but not limited to New York Heart Association (NYHA) Class III-IV heart failure, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 2.5 times the upper limit of normal, estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m², or severe infections (e.g., diabetic foot, sepsis, pneumonia, refractory infections).\n3. History of major cardiovascular or cerebrovascular events within the past 3 months.\n4. Pregnant or breastfeeding women.\n5. Currently using medications (other than the listed antihypertensives) that may affect aldosterone or renin secretion, including but not limited to sex hormones (e.g., oral contraceptives, estrogen replacement therapy), glucocorticoids (e.g., prednisone, dexamethasone), nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or antipsychotics (e.g., chlorpromazine, olanzapine).\n6. Individuals lacking or having restricted capacity for independent decision-making or action.\n7. History of psychiatric disorders.\n8. Poor compliance likely to compromise study completion.","75 Years",{"count":51,"type":20},406,"This prospective, single-center observational study aims to evaluate whether a steroid-based screening method can more accurately identify Primary Aldosteronism (PA) in hypertensive patients who remain on their usual antihypertensive medications, compared with the conventional aldosterone-to-renin ratio (ARR). PA is a common, potentially curable subtype of secondary hypertension that carries increased cardiovascular risk when undiagnosed or untreated. However, current screening protocols recommend \"medication washout\" or switching to minimally interfering drugs, which may pose safety concerns and add complexity.\n\nIn this study, approximately 406 participants (ages 18-75) with diagnosed hypertension and on at least one interfering antihypertensive drug (such as ACE inhibitors, ARBs, beta-blockers, diuretics, or calcium channel blockers) will be enrolled at the Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University. Each participant will undergo two rounds of blood sampling-first while continuing their usual antihypertensive regimen (the \"on-medication\" state) and second following a standardized washout\u002Fswitch period (the \"standard state\"), if medically feasible. At both stages, levels of plasma aldosterone, renin, and a broad panel of adrenal steroid hormones will be measured by liquid chromatography-tandem mass spectrometry.\n\nBy comparing diagnostic performance (e.g., sensitivity, specificity, and area under the receiver operating characteristic curve) of the steroid-based screening versus the ARR, the study seeks to determine whether steroid profiling improves accuracy under real-world treatment conditions. Findings may help refine PA screening strategies, reduce the need for extensive medication adjustments, and contribute to better clinical management of hypertension.",[24,54],"Hypertension",[56,57,58,24],"Steroid-Based Screening","Aldosterone-to-Renin Ratio (ARR)","Machine Learning","2026-04-23",{"date":61,"type":33},"2026-04-28",{"date":63,"type":33},"2025-04-15",{"date":65,"type":20},"2026-12-30",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":74,"targetDuration":76,"studyType":21,"phases":4,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100632355","environment-inflammation-and-metabolic-diseases-study-100632355","NCT07512609","Environment, Inflammation and Metabolic Diseases Study","Inclusion Criteria:\n\n* All individuals who voluntarily participated in the physical examination\n\nExclusion Criteria:\n\nParticipants with incomplete data",true,{"count":75,"type":20},8000,"5 Years","The aim is to establish an effective and practical early warning model for endocrine and metabolic diseases based on an environmental-gene-protein panoramic network, to uncover new mechanisms underlying the onset and progression of these diseases, and to screen for novel therapeutic targets.",[79,80,54,81],"Endocrine Disease","Metabolic Disorders","Diabetes Mellitus",[79,80,54,81],"2026-04-01",{"date":85,"type":33},"2026-04-06",{"date":87,"type":33},"2020-12-25",{"date":89,"type":20},"2026-12-31",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100580141","68ga-pentixafor-petct-versus-adrenal-vein-sampling-in-diagnosing-unilateral-subtype-of-primary-aldosteronism-concurrent-with-autonomous-cortisol-secretion-predict-100580141","NCT06833437","68Ga-Pentixafor PET\u002FCT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT)","68Ga-Pentixafor PET\u002FCT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT): a Randomized Cross-over Trial","Inclusion Criteria:\n\n* Getting the written informed consent;\n* PA conccurent with autonomous cortisol secretion;\n* Patients with hypertension aged 18-70 years;\n* CT or MRI scan of the adrenal glands with adenoma. Exclusion criteria\n\nExclusion Criteria:\n\n* Unable to complete 68Ga-Pentixafor PET\u002FCT or AVS;\n* Refusal of surgery or contraindications for surgery;\n* PA patients who meet the by-passing AVS criteria \\[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \\>300pg\u002Fml\\]\n* Suspicion of familial hyperaldosteronism or Liddle syndrome. \\[i.e., age \\\u003C20 years, hypertension and hypokalemia, or with family history\\];\n* Suspicion of pheochromocytoma or adrenal carcinoma;\n* Patients with actively malignant tumor;\n* Patients who have adrenalectomy history;\n* Long-term use of glucocorticoids;\n* Pregnant or lactating women; with alcohol or drug abuse and mental disorders;\n* Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV; History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; Severe anemia (Hb\\\u003C60g\u002FL); Serious liver dysfunction or chronic kidney disease aspartate aminotransferase (AST) or alanine transaminase (ALT) \\>3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73 m2); Systemic Inflammatory Response Syndrome (SIRS); Uncontrolled diabetes (FBG≥13.3 mmol\u002FL); Obesity (BMI≥35 kg\u002Fm²) or Underweight (BMI≤18 kg\u002Fm²); Untreated aneurysm; Other comorbidity potentially interfering with treatment;\n* Suspected PBMAH or PPNAD;\n* Poor compliance or any other reason deemed unsuitable for inclusion by the investigators;\n* Patients with adrenal insufficiency requiring hormone replacement therapy.",{"count":99,"type":20},178,"INTERVENTIONAL",[102],"NA","To validate the accuracy of 68Ga-Pentixafor PET\u002FCT and adrenal venous sampling (AVS) in subtype diagnosis of PA\u002FACS patients with adrenal nodules, based on biochemical and clinical remission outcomes, and to determine whether the diagnostic accuracy of 68Ga-Pentixafor PET\u002FCT is non-inferior to AVS.",[24,25],[106,107,108,109,110,111],"Primary aldosteronism","Autonomous cortisol secretion","Adrenal venous sampling","68Ga-Pentixafor PET\u002FCT","outcome","multicenter randomized crossover trial","2026-02-03",{"date":114,"type":33},"2026-02-05",{"date":116,"type":33},"2024-08-01",{"date":118,"type":20},"2029-12-31",{"name":39,"class":40},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":129,"studyType":21,"phases":4,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":41},"100564962","accuracy-of-68ga-pentixafor-petct-for-subtypting-diagnosis-in-patients-with-primary-aldosteronism-concurrent-with-autonomous-cortisol-secretion-100564962","NCT06635993","Accuracy of 68Ga-Pentixafor PET\u002FCT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion","ABOARD","Inclusion Criteria:\n\n1. Getting the written informed consent\n2. The clear diagnosis of primary aldosteronism；\n3. Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) ≥50 nmol\u002Fl；\n4. Patients who are willing to undergo surgery；\n5. Adrenal CT or MRI scan of the adrenal glands with nodule (≥1cm).\n\nExclusion Criteria:\n\n1. PA patients who meet the by-passing AVS criteria \\[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \\>300pg\u002Fml\\]；\n2. Suspicion of familial hyperaldosteronism or Liddle syndrome. \\[i.e., age \\<20 years, hypertension and hypokalemia, or with family history\\]；\n3. Suspicion of pheochromocytoma or adrenal carcinoma；\n4. Patients with actively malignant tumor；\n5. Patients who have adrenalectomy history；\n6. Long-term use of glucocorticoids；\n7. Patients who are allergic to contrast media and cannot tolerate AVS；\n8. Pregnant or lactating women; with alcohol or drug abuse and mental disorders；\n9. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV; History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; Severe anemia (Hb\\<60g\u002FL); Serious liver dysfunction or chronic kidney disease aspartate aminotransferase (AST) or alanine transaminase (ALT) ≥3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \\<30 ml\u002Fmin\u002F1.73 m2); Systemic Inflammatory Response Syndrome (SIRS); Uncontrolled diabetes (FBG≥13.3 mmol\u002FL); Obesity (BMI≥35 kg\u002Fm²); Untreated aneurysm; Other comorbidity potentially interfering with treatment；\n10. Consider patients with bilateral cortisol hypersecretion such as PBMAH or PPNAD.",{"count":128,"type":20},97,"6 Months","To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and\u002For postoperative remission as the reference standard for classification diagnosis.",[132],"Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion",[134,135,108,109],"primary aldosteronism","autonomous cortisol secretion","2024-10-09",{"date":138,"type":33},"2024-10-10",{"date":140,"type":33},"2024-08-12",{"date":142,"type":20},"2027-08-12",{"name":39,"class":40},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":41},"100562012","pathological-typegene-mutation-and-clinical-characteristics-of-unilateral-primary-aldosteronism-100562012","NCT06597630","Pathological Type，Gene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism","Pathological Type，Gene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism，A Prospective Study","Inclusion Criteria:\n\n1. No gender limitation;\n2. Age 18-80 years old;\n3. The patient was diagnosed with UPA and underwent total adrenal resection.\n\nExclusion Criteria:\n\n1. Bilateral disease\n2. Partial of no biochemical response in follow-up\n3. partial adrenalectomy","80 Years",{"count":153,"type":20},100,"1. Aim to investigate the pathological feature of UPA in Asians\n2. To clarify the relationship between pathology, clinical phenotype, genetic mutation and surgical outcome of UPA in Asians.\n3. To explore a new pathological type of unilateral primary aldosterone",[24],[157,158],"Pathological type","Gene mutation","2024-09-13",{"date":161,"type":33},"2024-09-19",{"date":163,"type":33},"2023-12-01",{"date":165,"type":20},"2024-12-31",{"name":39,"class":40},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":174,"targetDuration":4,"studyType":100,"phases":176,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100551206","phase-4-finerenone-for-patients-with-primary-aldosteronism-fairy-100551206","NCT06457074","Finerenone for Patients With Primary Aldosteronism (FAIRY)","Finerenone for Patients With Primary Aldosteronism (FAIRY): A Multicenter, Randomized Clinical Trial","Inclusion Criteria:\n\n1. . Aged between 18-75, male or female;\n2. . With confirmed PA diagnosis (screening positive and at least one confirmatory test is positive); NOTE: Screening positive was defined as plasma aldosterone-to-renin ratio (ARR)\n\n   ≥ 20(pg\u002Fml)\u002F(μIU\u002Fml) or ARR≥30(ng\u002FdL)\u002F(ng\u002Fml\u002Fhr). Plasma aldosterone concentration (PAC) post captopril challenge test (CCT) ≥ 110 pg\u002Fml or PAC post seated saline infusion test (SSIT) ≥ 80 pg\u002Fml was considered positive. Note: ARR≥10(pg\u002Fml)\u002F(μIU\u002Fml) or ARR≥15(ng\u002FdL)\u002F(ng\u002Fml\u002Fhr) can be considered positive if the patients with hypokalemia (serum potassium \\\u003C 3.5mmol\u002FL) or adrenal nodules (diameter \\> 1cm).\n3. . Not taking any antihypertensive drugs or on a stable regimen of antihypertensive agents(Limited to alpha-adrenergic receptor blockers and calcium channel blockers.) for more than four weeks before screening;\n4. . With a mean seated office SBP≥140 or DBP≥90 mmHg;\n5. . Able and willing to give informed consent for participation in the clinical study;\n\nExclusion Criteria:\n\n1. Has a plan to conduct PA subtype classification(eg. Adrenal vein sampling, PET-CT) in 3 months；\n2. Has planned surgery within 3 months;\n3. With a mean seated office SBP ≥ 180mmHg or DBP ≥ 110mmHg before randomization; Note: Mean seated BP is defined as the average of 3 seated BP measurements at any single clinical site visit. If the patient did not take their regularly scheduled antihypertensive medications prior to the visit, 1 BP re-test is allowed within 2 days after taking the medications.\n4. Night shift workers;\n5. Has a body mass index(BMI) ≥30 kg\u002Fm2 at screening;\n6. Has uncontrolled diabetes with fasting blood glucose(FBG)≥13.3mmol\u002FL at screening;\n7. Has uncontrolled chronic diseases;\n8. Has known other secondary hypertension (eg, renal artery stenosis, Cushing's syndrome, pheochromocytoma, or aortic coarctation) except subclinical Cushing's syndrome;\n9. Has known and documented heart failure (New York Heart Association (NYHA) class III or IV), liver transaminase levels were more than 2 times higher than the upper limit of normal;\n10. Has had CABG or other major cardiac surgery (eg, valve replacement), peripheral arterial bypass surgery, or PCI within 6 months before Screening;\n11. Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before screening;\n12. Has poor compliance that can not fully participating in the study;\n13. Has hyperkalemia with serum potassium \\> 5.0mmol\u002FL without potassium supplementation;\n14. Has a history of uncontrolled malignant tumor;\n15. Has more than 20mmHg difference of seated office SBP in both arms;\n16. Is not willing or not able to stop taking sex hormones, glucocorticoids, non-steroidal anti-inflammatory drugs, cyclosporine, tacrolimus, or antidepressants;\n17. Is pregnant, breastfeeding, or planning to become pregnant during the study;\n18. Complicated with severe mental illness;\n19. Has had prior solid organ transplant and\u002For cell transplants;\n20. Has a history of allergy to Finerenone or spironolactone;\n21. Has typical consumption of ≥15 alcoholic drinks weekly. Note: 1 drink of alcohol is equivalent to 360ml beer, 45ml spirits, or 150ml wine;\n22. Has participated in another clinical study involving any investigational drug within 30 days prior to screening；\n23. Female of childbearing potential refuses to use non-hormonal contraception methods during the study period;\n24. Refuse to stop eating grapefruit or grapefruit juice during treatment with Finerenone;\n25. Other situations that the investigator assesses the subject as unable to complete the trial.",{"count":175,"type":20},306,[177],"PHASE4","Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).",[24],[106,181,182,183,184],"Finerenone","Spironolactone","Antihypertensive effect","Safety","2024-08-28",{"date":187,"type":33},"2024-08-30",{"date":189,"type":33},"2024-06-04",{"date":191,"type":20},"2026-06-01",{"name":39,"class":40},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":201,"targetDuration":4,"studyType":100,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":41},"100534392","outcome-of-68ga-pentixafor-petct-versus-adrenal-vein-sampling-in-primary-aldosteronism-100534392","NCT06238232","Outcome of 68Ga-Pentixafor PET\u002FCT Versus Adrenal Vein Sampling in Primary Aldosteronism","68Ga-Pentixafor PET\u002FCT Versus Adrenal Vein Sampling to Determine Treatment in Primary Aldosteronism: A Multicenter Randomized Clinical Trial","GAPA","Inclusion Criteria:\n\n(1)Getting the written informed consent (2)ARR ≥20 (pg\u002Fml)\u002F (μIU\u002Fml) or ARR ≥ 30(ng\u002FdL)\u002F(ng\u002Fml\u002Fhr) plus at least one positive PA confirmatory test (CCT, SSIT).\n\n(3)Patients who are willing to undergo surgery. (4)Patients with hypertension aged 18-70 years. (5)CT or MRI scan of the adrenal glands with nodule (≥1cm). Exclusion criteria\n\n1. Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) ≥50 nmol\u002Fl.\n2. PA patients who meet the by-passing AVS criteria \\[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \\>300pg\u002Fml\\]\n3. Suspicion of familial hyperaldosteronism or Liddle syndrome. \\[i.e., age \\\u003C20 years, hypertension and hypokalemia, or with family history\\]\n4. Suspicion of pheochromocytoma or adrenal carcinoma.\n5. Patients with actively malignant tumor.\n6. Patients who have adrenalectomy history or with adrenocortical insufficiency.\n7. Long-term use of glucocorticoids.\n8. Pregnant or lactating women; with alcohol or drug abuse and mental disorders.\n9. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV; History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; Severe anemia (Hb\\\u003C60g\u002FL); Serious liver dysfunction or chronic kidney disease aspartate aminotransferase (AST) or alanine transaminase (ALT) \\>3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73 m2); Systemic Inflammatory Response Syndrome (SIRS); Uncontrolled diabetes (FBG≥13.3 mmol\u002FL); Obesity (BMI≥35 kg\u002Fm²) or Underweight (BMI≤18 kg\u002Fm²); Untreated aneurysm; Other comorbidity potentially interfering with treatment",{"count":202,"type":20},320,[102],"To compare the 68Ga-Pentixafor PET\u002FCT and adrenal vein sampling on the long-term outcomes of primary aldosteronism (PA) patients with adrenal nodule (≥1cm)",[24],[207,108,109,110,208],"Primary aldosteronism;","multicenter randomized","2024-04-27",{"date":211,"type":33},"2024-04-30",{"date":213,"type":33},"2024-01-09",{"date":215,"type":20},"2027-12-31",{"name":39,"class":40},""]